Substances

Standards, Ethics, and Integration: Rebuilding Trust in the Ketamine Industry

November 19, 2024
Featuring: Juan Pablo Cappello

While the psychedelic industry is facing intense growing pains, the ketamine industry has been allowed to grow, largely unchecked. How did we get here, and how does the ketamine space rebuild trust?

Subscribe Share

While the psychedelic industry is facing intense growing pains, the ketamine industry has been allowed to grow, largely unchecked. How did we get here, and how does the ketamine space rebuild trust?

In this episode, Kyle interviews Juan Pablo Cappello: co-founder and former CEO of Nue Life Health, whose assets were subsequently acquired by Beckley Waves.

Cappello discusses the current challenges and controversies facing a ketamine industry that has moved much faster than anyone anticipated, and stresses the need to create industry-wide standards – especially for at-home ketamine – before the government imposes its own standards on us. Citing the Matthew Perry case and other bad behavior from providers, he talks about the risks of overpromising and underdelivering, the lack of integration in the majority of ketamine frameworks, and how profit-driven, subscription model motives have overshadowed patient care and ethical practices.

He also discusses:

  • The complications from personal perspectives and passions shifting after a psychedelic experience, and how that can change over time
  • The FDA’s recent rejection of MDMA: What would have happened to MDMA if it had been approved?
  • Hope for more Native American churches, and what they can learn from the DEA’s denial of Soul Quest
  • The story of a bump of cocaine ruining the hope for cannabis to be decriminalized under the Carter administration
  • Our current Wild West of gas station CBD, Delta-8, and barely-regulated vapes

and more! 

Links

PT274 – Juan Pablo Cappello – Nue Life: Using Digital Phenotyping to Personalize Healthcare

PT496 – Maintenance Doses and Recurring Revenue: The Ethics of At-Home Ketamine Therapy, featuring: Juan Pablo Cappello

How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence, by Michael Pollan

Why Did the FDA Reject MDMA-Assisted Therapy for PTSD?, featuring: Ingmar Gorman, Ph.D.

Nytimes.com: How Psychedelic Research Got High on Its Own Supply

Marciamoorestory.com

One Year podcast: 1977: Mr. Marijuana and the Drug Czar

Wikipedia.org: Cole Memorandum

Nbcnews.com: Off-duty Alaska Airlines pilot said he took ‘magic mushrooms’ 48 hours before allegedly trying to shut down plane engines

Churchofeagleandcondor.org

The United States Court of Appeals for the Eleventh Circuit’s Non-Argument Calendar against Soul Quest

Psychedelics, Religion, and the DEA’s Quest for Soul

Ketamine and Trauma Treatment

Psychedelic Education Center: Black Friday deals are open now!

*Amazon links are affiliate links, meaning that Psychedelics Today will receive a percentage of the sale

Juan Pablo Cappello 3

In this Episode

Juan Pablo Cappello

Juan Pablo Cappello is the co-founder and the former CEO of Nue LIfe Health, whose assets were subsequently acquired by Beckley Waves. While at Nue Life, Juan Pablo oversaw a team that supported 10,000 patients and facilitated almost 100,000 legal ketamine experiences. Juan Pablo currently sits on the board of a public company (NYSE: TBBB). The opinions expressed are solely Mr. Cappello’s and are focused on the at-home ketamine industry and not any one provider in particular.

Socials: Linkedin